Vertex Pharmaceuticals Incorporated (BIT:1VRTX)
Italy · Delayed Price · Currency is EUR | Market Cap | 91.64B -17.7% |
| Revenue (ttm) | 10.60B +10.1% |
| Net Income | 3.76B |
| EPS | 14.62 |
| Shares Out | n/a |
| PE Ratio | 24.36 |
| Forward PE | 21.27 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1 |
| Average Volume | 10 |
| Open | 361.90 |
| Previous Close | 359.40 |
| Day's Range | 361.90 - 361.90 |
| 52-Week Range | 316.00 - 429.80 |
| Beta | n/a |
| RSI | 36.62 |
| Earnings Date | May 4, 2026 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMK... [Read more]
News
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therap...
These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported mixed financial results for the first quarter after the market close on Monday.
Vertex Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 revenue rose 8% year-over-year to $2.99B, with strong growth in CF and new products like ALYFTREK, CASGEVY, and JOURNAVX. Robust R&D and commercial execution support 2026 guidance of $12.95–$13.1B revenue and over $500M from non-CF products.
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Vertex Pharmaceuticals on Monday beat Wall Street estimates for first-quarter adjusted profit, helped by a near eight-fold surge in sales of its new cystic fibrosis treatment.
Vertex Reports First Quarter 2026 Financial Results
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2026, and reiterated its full year 2026 ...
Vertex to Announce First Quarter 2026 Financial Results on May 4th
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2026 financial results on Monday, May 4, 2026, after the financial markets close. The company ...
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/i...
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Vertex Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference
Diversification beyond cystic fibrosis is driving growth, with strong launches in renal, hematology, and pain. Povetacicept phase III data showed best-in-class efficacy and safety, with regulatory submission imminent. JOURNAVX and ALYFTREK are fueling commercial momentum across multiple geographies.
This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results
Vertex Pharmaceuticals (VRTX) shares are soaring after the company said it achieved "remarkable" results from a new clinical trial.
Vertex passes key test In quest to treat kidney diseases
Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company's plan to expand into kidney disease.
Vertex Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Leadership outlined four strategic goals for 2026, including pipeline advancement and commercial diversification. POVI in IgAN delivered strong efficacy and safety data, with regulatory filing accelerated to this month. JOURNAVX and CASGEVY are positioned for multibillion-dollar growth, supported by robust clinical and real-world data.
Vertex's kidney disease drug meets main goal in late-stage trial
Vertex Pharmaceuticals said on Monday that its experimental kidney disease drug met the main goal of a late-stage trial.
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive data from a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetaci...
Vertex to Participate in Upcoming March Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial...
Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from a Phase 4 study of JOURNAVX® (suzetrigine), a prescription non-opioid pain signal inhibitor for th...
Vertex Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Leadership in CF is expanding into renal, heme, and pain, with pivotal programs advancing and a strong balance sheet supporting innovation. Pove in IgAN is nearing key data and regulatory milestones, while next-gen CF therapies and diversified R&D drive future growth.
Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in TD Cowen's 46th Annual Health Care Conference. Reshma Kewalramani, President and...
Vertex Pharmaceuticals Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw strong revenue and earnings growth, driven by CF franchise strength, new launches (CASGEVY, JOURNAVX), and pipeline progress. 2026 guidance projects 8–9% revenue growth, with significant contributions from non-CF products and continued investment in innovation.
Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments
Vertex Pharmaceuticals forecast 2026 revenue largely in line with analysts estimates on Thursday, as the drugmaker bets on growth for its cystic fibrosis treatments as well as contributions from newer...
Vertex Reports Fourth Quarter and Full Year 2025 Financial Results
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2025, and provided its...
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager
SHANGHAI, Feb. 2, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license ...
Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil
The Investment Committee give you their top stocks to watch for the second half.
Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, after the financial mark...
Vertex Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted a robust pipeline with major growth expected from CF, Casgevy, JOURNAVX, and the upcoming launch of Povy for IgAN. Expansion into new geographies and indications, strong financials, and a focus on innovation and commercial execution position the company for sustained growth.